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The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare
directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and
practice then the chosen outcomes need to be relevant and important to key stakeholders including patients and
the public, health care professionals and others making decisions about health care. There is a growing recognition
that insufficient attention has been paid to the outcomes measured in clinical trials. These issues could be
addressed through the development and use of an agreed standardized collection of outcomes, known as a core
outcome set, which should be measured and reported, as a minimum, in all trials for a specific clinical area.
Accumulating work in this area has identified the need for general guidance on the development of core outcome
sets. Key issues to consider in the development of a core outcome set include its scope, the stakeholder groups to
involve, choice of consensus method and the achievement of a consensus.
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Clinical trials seek to evaluate whether an intervention is
effective. This is determined by comparing outcomes
that are chosen to reflect beneficial and harmful effects.
Outcomes may be specific (for example, progression of
loss of eyesight in patients with retinal degeneration) or
they may be a broad construct used to demonstrate
effects of an intervention on one aspect of health (for
example, pain). Selection of appropriate outcomes or
domains is crucial when designing clinical trials to com-
pare directly the effects of different interventions in ways
that minimize bias. If the findings are to influence policy
and practice then the chosen outcomes need to be rele-
vant and important to key stakeholders including
patients and the public, health care professionals and
others making decisions about health care.
There is a growing recognition that insufficient atten-
tion has been paid to the outcomes measured in clinical
trials. Difficulties caused by heterogeneity in outcome
measurement are well-known to systematic reviewers. For* Correspondence: prw@liv.ac.uk
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distribution, and reproduction in any mediumexample, the most accessed and the top cited Cochrane
Reviews in 2009 [1] all describe problems due to inconsist-
encies in the outcomes reported in trials. Furthermore,
empirical research provides strong evidence that outcome
reporting bias, defined as the results-based selection for
publication of a subset of the original measured outcome
variables, is an important problem in randomized trials [2]
that affects the conclusions in a substantial proportion of
Cochrane reviews [3]. Outcome reporting bias is likely to
affect systematic reviews more widely, as well as published
research in general.
These issues could be addressed through the develop-
ment and use of an agreed standardized collection of out-
comes, known as a core outcome set (COS), which should
be measured and reported in all trials for a specific clinical
area [4]. These sets do not imply that outcomes in a par-
ticular trial should be restricted to those in the COS. Ra-
ther, there is an expectation that the core outcomes will
always be collected and reported, and that researchers will
continue to explore other outcomes. In most trials, the
primary outcome would be expected to be one of those
contained in the COS. If a COS is not implemented in a
particular trial, the researchers should explain their deci-
sion in the trial protocol and subsequent report. Similarly,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the COS, then the relevance and importance of the chosen
outcome should be explained. This approach would en-
hance the value of evidence synthesis by reducing hetero-
geneity in reported outcomes between trials and reducing
the risk of outcome reporting bias, since trial reports will
always include presentation of their findings for the core
outcomes, as a minimum. Statistical power would be
increased because fewer studies would have to be omitted
from meta-analyses. The GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation) group
(http://www.gradeworkinggroup.org) recognize the need
to identify a relevant set of core outcomes, and recom-
mends that up to seven patient-important outcomes are
listed in the ‘Summary of Findings’ tables in systematic
reviews. This is supported by Cochrane Reviews of the
effects of healthcare interventions [5,6] and by the World
Health Organization (WHO) in developing guideline
recommendations [7].
An important rationale for COS is that outcomes
reported for trials may not reflect endpoints that are
meaningful for health service users. Examples exist
where patients identified an outcome important to them
as a group that might not have been considered by prac-
titioners on their own [8-12]. Recognition of the import-
ance of incorporating health service user opinion in
COS development is increasing, but involvement has
been limited to date.
The most notable work relating to outcome
standardization has been conducted by the OMERACT
(Outcome Measures for Rheumatology Clinical Trials)
collaboration since 1992, which advocates the use of
COS in clinical trials in rheumatology [13]. More than
50 other groups have been working on COS in specific
areas of health care, including pain [14], maternity care
[15] and some pediatric specialties [16].
The COMET (Core Outcome Measures in Effectiveness
Trials) Initiative [17] brings together researchers interested
in the development, application and promotion of COS,
derived using rigorous consensus methods, for effective-
ness trials. COMET aims to collate and stimulate the
development of relevant resources, both applied and meth-
odological, to facilitate exchange of ideas and information,
to work with patients, the public and their representatives
to develop material to improve health service user engage-
ment, and to foster methodological research in the area of
COS. Data on relevant individual studies, both published
and ongoing, are being included in a free, publically avail-
able internet-based resource. This is a unique resource,
which is updated periodically, and which should serve to
minimize duplication of effort in the development of COS.
As each COS is developed, it will be important to agree
on an appropriate instrument or definition for each
included outcome. Examples of lack of validatedinstruments and standardized definitions abound in the
literature. For example, fewer than 20% of 906 different
outcomes measured in breast reconstruction surgery trials
were defined or measured with a validated tool [18,19].
Accumulating work in this area has identified the need
for general guidance on the development of COS. We
identify here key issues to consider and methodological
decisions to be made, referencing illustrative examples.
Study protocols, in which key decisions are documented
regarding the choices made in the process of COS devel-
opment, are emerging, for example in the MOMENT
study (The management of otitis media with effusion in
children with cleft palate: a feasibility study http://www.
hta.ac.uk/project/2555.asp) and the development of COS
for surgery for colorectal and esophageal cancer, morbid
obesity and breast reconstruction.
Main text
Suggested approach for development of a core outcome
set
Scope
The specific area of health or healthcare to which the
COS is to apply needs to be described, with details of
health condition, population and types of interventions.
The COS may be developed to encompass all stages or
severity of a health condition or it may be focused on a
particular disease category. For example, in colorectal
cancer, a COS may be developed for all patients or it
may focus on patients with metastatic disease. Similarly,
the core set may be developed for all treatment types or
for a particular intervention (for example, COS may be
created for use in all trials of interventions to treat mor-
bid obesity or for bariatric surgery alone).
Identifying existing knowledge
One of the difficulties in this area of research is how to
identify studies that have already been done (or are
underway) to develop COS. As part of the COMET Ini-
tiative, a searchable database has been developed [17].
This enables researchers to check for existing or ongoing
work before embarking on a new project, thus minimiz-
ing duplication of effort.
A review of previous trials [20] or systematic reviews
in the area can provide evidence of need for a COS and
also identify a potential list of outcomes. Systematic
reviewers are starting to use the outcome matrix recom-
mended by the ORBIT project [3] to display the out-
comes reported in the eligible studies. This matrix may
demonstrate the inconsistency of outcomes measured to
date in addition to potential outcome reporting bias. A
review of studies other than clinical trials (for example,
observational research into harms) may also identify
additional outcomes, such as rare endpoints, that would
be worthy of consideration for inclusion in the COS.
Williamson et al. Trials 2012, 13:132 Page 3 of 8
http://www.trialsjournal.com/content/13/1/132Stakeholder involvement
Key stakeholders may include patients and the public,
health care practitioners, regulators, industry represen-
tatives, and researchers. Bringing diverse stakeholders
together to try to reach a consensus is increasingly well-
accepted as the future of collaborative, influential re-
search. An important example of this is the work of the
James Lind Alliance in determining important questions
about treatments where uncertainty remains [21]. Deci-
sions regarding the stakeholder groups to be involved
and the target number from each group will be
dependent upon the particular scope of the COS as well
as upon existing knowledge and practical feasibility con-
siderations. These decisions should be documented and
explained in the study protocol. Consideration should be
given to potential conflicts of interest within the group
developing the COS (for example, the developers of
measurement instruments in the area of interest or
those whose work is focused on a specific outcome)
[22].
Few COS studies to date have involved patients or the
public, yet those that have done so have identified out-
comes that were not previously identified by the other sta-
keholders [4,5,23-26]. Methods for identifying patients or
their representatives include clinics, patient societies, advo-
cacy groups, and care giver support groups. To achieve
representativeness, it may be helpful to consider approach-
ing practitioners with the support of professional bodies.Consensus methods
The first step in the process is typically to develop con-
sensus about ‘what’ to measure. The ‘how’ and ‘when’ to
measure are usually later in the process but may be
determined by consensus methods as well. Groups that
first establish consensus about what concepts to meas-
ure may subsequently conclude that there is a single
measurement instrument for an outcome in the COS
that is supported by sufficient evidence to recommend
its use. However they may identify that gaps in outcome
measurement exist, either because there is no ideal
instrument for a particular concept or because the evi-
dence base for existing instruments is of limited quality.
These limitations may make it difficult to identify which
of several potential measures may be preferable for use
in the relevant context. The COSMIN (COnsensus-
based Standards for the selection of health Measure-
ment Instruments, www.cosmin.nl) checklist [27] can
be used as a tool for developing studies of the validity
and reliability of measurement instruments because it
describes the necessary design requirements for the as-
sessment of those measurement properties. In addition,
feasibility of measurement is a further consideration
[13].Methods used in previous studies to elicit opinions
and to develop consensus about important outcomes in-
clude expert panel meetings [28], Delphi surveys [22],
Nominal Group Techniques [13], focus groups [24], in-
dividual interviews [25] and individual questionnaires
[5]. Considerations concerning the choice of method in-
clude the need to build a true consensus with methodo-
logical rigor, strategies to ensure that a diverse range of
opinions are heard, and factors such as financial and car-
bon costs that might limit the practicality of face-to-face
meetings. It is important to ensure that views from all
key stakeholder groups are included when making the
final decision regarding the COS. This can be achieved
through anonymous voting facilitated through email or
keypads at meetings.
It is necessary to decide what information about pos-
sible outcomes should be given to stakeholder participants
before a consensus exercise begins. A literature review of
relevant studies showing the outcomes clinicians value
and report most frequently, which may include informa-
tion about methods to measure the identified outcomes
and when to measure them, has been proposed [18-20].
This should be combined with outcomes deemed to be
important to health service users if such work has been
undertaken previously. If consensus participants are
shown a list of potential outcomes, it is generally recom-
mended that they be given the opportunity to propose the
inclusion of additional items, especially as the literature
may not include outcomes associated with the most re-
cent treatments available. Because this has the potential to
result in a long list of items, criteria for determining inclu-
sion of items to be considered in the consensus exercise
may be needed. For example, Devane et al. [15] required
new items to have been suggested by at least two partici-
pants. If it is felt that the sharing of a list of outcomes at
the outset of the consensus process may bias responses,
open questioning may be preferred. Techniques to do this
include administering questionnaires [5], focus groups
[24] and in-depth interviews [25], to determine outcomes
important to patients. However this may lead to stake-
holders not considering areas previously deemed import-
ant, and subsequent questions to prompt consideration of
specific outcomes may be warranted.
Researchers should consider the potential impact of
the following methodological decisions on the final
results: group composition, questioning technique, the
information participants receive to inform their answers,
whether or not responses are anonymous, how the
group participants interacted with or influenced each
other, the medium of the interaction, attrition bias, ana-
lysis which can miss or overstate the importance of cer-
tain outcomes, and the way in which consensus is
reached. A single heterogeneous consensus panel com-
prising the various stakeholders may be deemed
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separate panels for different stakeholder groups followed
by work to integrate the multiple perspectives may be
more appropriate for others. A variety of methods have
been used to date in published and ongoing studies, par-
ticularly related to the inclusion of the patient perspec-
tive. The proportion of patients and health service users
chosen in a Delphi survey may depend upon the clinical
setting; for example, for breast reconstructive surgery,
which is an optional procedure undertaken for cosmetic
purposes, the involvement of patients is more critical
than in other settings. A research project has recently
started within the COMET Initiative to assess the effect-
iveness of these different methods.
Consideration should be given in advance to the cri-
teria that will be used to determine when consensus has
been achieved. A review of the reporting of Delphi stud-
ies to develop COS demonstrated poor reporting of the
methods used [29]. As an example definition, in a Delphi
survey participants may be asked to score each outcome
from a long list using the scale proposed by the GRADE
group [http://www.gradeworkinggroup.org], in which 1
to 3 signifies an outcome of limited importance, 4 to 6
important but not critical, and 7 to 9 critical. A number
of rounds may be held in which responses are summar-
ized and fed back to individuals, allowing them to
change their score in light of the group’s opinion. Con-
sensus regarding whether an outcome should be in the
COS could be defined as 70% or more of the respon-
dents scoring it 7 to 9 and fewer than 15% scoring it as
1 to 3. Consensus that an outcome should not be
included in the COS could, for example, be defined as
70% or more scoring it as 1 to 3 and fewer than 15%
scoring it as 7 to 9. All other score distributions would
be taken to indicate lack of agreement for inclusion of a
given outcome in the COS. The rationale for these
thresholds is that acceptance that consensus has been
reached for an outcome to be included in the COS
requires agreement by the majority regarding the critical
importance of the outcome, with only a small minority
considering it to have little or no importance. Likewise,
for consensus to have been reached that an outcome
should not be in the COS requires agreement by the ma-
jority that the outcome is of little or no importance, with
only a small minority considering it to be critically im-
portant. Whereas choice of thresholds is somewhat sub-
jective, specification of the definition in the study
protocol should reduce the risk that researchers will de-
fine consensus post-hoc in a way that would bias the
conclusions toward their own beliefs.
Consideration should be given in advance to the possi-
bility that consensus may not be achieved. For example,
different stakeholders may disagree about the inclusion
of specific outcomes in the COS. This might lead to adecision to recommend the smaller COS, about which
there is consensus.
Achieve global consensus
To compare and contrast all research in a topic area, a
COS must be applicable and adopted across inter-
national settings and across relevant disciplines. Expert
panels and conference workshops have been used to
achieve international consensus [13].
Review with feedback and updating as necessary
Opportunities to review the COS periodically are import-
ant as a form of validation, to ensure outcomes are still
relevant and important, to allow the chance to add new
outcomes, to evaluate how successful implementation has
been and to engage further stakeholders as appropriate.
The question of who should be developing and reviewing
COS (for example, professional organizations or groups of
trialists in particular therapeutic areas) needs careful con-
sideration to ensure continued support for the activity.
Implementation of core outcome set
To increase COS uptake, it is recommended that develo-
pers consider engagement with the relevant Cochrane
Review Groups, clinical guideline developers, research
funders, journal editors, regulators such as research eth-
ics committees, and trial registries. For example, the
NIHR Health Technology Assessment funding body in
the UK has recently added the following statement to its
application form:
‘Details should include justification of the use of
outcome measures where a legitimate choice exists
between alternatives.
- Where established Core Outcomes exist they should be
included amongst the list of outcomes unless there is
good reason to do otherwise. Please see The COMET
Initiative website at www.comet-initiative.org to identify
whether Core Outcomes have been established.’
Potential barriers and cost implications of implement-
ing the COS should be considered.
Clear and transparent presentation
Reporting standards for studies specifically using Delphi
methods to achieve consensus about a COS have been
recommended [29]. We propose the checklist in Table 1
to improve the reporting quality of studies to develop
consensus around domain concepts or what to measure
more generally.
This includes declaration of potential conflicts of
interests within the COS development study team to
avoid concerns that individuals with vested interests; for
Table 1 Checklist of the items that groups should consider when reporting the development of a COS of domain
concepts (that is, ‘what’ to measure)
Section/topic # Checklist item
TITLE
Title 1 Identify the report as a study to develop a COS.
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background, objectives, data sources, participant
eligibility criteria, study methods, results, limitations, conclusions, and implications of key findings.
INTRODUCTION
Rationale 3 Describe the rationale for the development of a COS in the context of what is already known. This may
include a review of outcomes in previous trials or systematic reviews.
Objectives 4 Provide an explicit statement of questions being addressed with reference, as applicable, to: health condition,
population, and types of intervention(s).
METHODS
Protocol and registration 5 Indicate if a study protocol exists, and where it can be accessed (for example, web address)
Eligibility criteria 6 Specify participant eligibility criteria, including stakeholder group, the rationale for involving them, and how
participants were identified and sampled.
Information sources 7 Describe all information sources (for example, systematic review, databases with dates of coverage, contact
with study authors) provided to participants before the start of and during the consensus process. If no
information on previously measured outcomes is provided, this should be clearly stated together with
details of the method for obtaining information on outcomes of importance from the participants.
Consensus process 8 Describe method to determine consensus and the rationale. A checklist for reporting Delphi methods
applied to the development of COS has previously been recommended [29].
Outcome scoring 9 Describe how outcomes will be scored during the consensus exercise, and how scores will be summarized
across participants during each stage of the consensus process.
Definition of consensus 10 Clearly describe any pre-determined definition of consensus. Describe procedure for determining how
outcomes will be included or excluded from consideration at each stage of the consensus process.
RESULTS
Participants 11 Give the total number of participants invited and the number involved in each aspect of the study. Give the
proportion of each type of participant from the various stakeholder groups involved. Present any data
collected on participant characteristics.
Results of the consensus
process
12 As a minimum, provide a comprehensive list of all the outcomes that participants agreed should be included
in the core set. Describe a measure of group response and distribution of response for each outcome
considered during the process.
DISCUSSION
Summary of evidence 13 Summarize the main findings regarding the level of consensus and the content of the COS. Consider its
relevance to key groups e.g. patients and the public, healthcare providers, and policy makers, and any
potential barriers to implementation.
Limitations 14 Discuss limitations in terms of stakeholder and geographical coverage. Describe methods used for assessing
risk of bias, in relation to information provided to participants beforehand, attrition, any lack of anonymity, etc.
Conclusions 15 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Funding and editorial independence
Funding 16 Describe sources of funding and the role of the funder in the study.
Conflicts of interest 17 Describe any conflicts of interest within the study team, for example researchers who have developed an
outcome measurement instrument applicable to the scope of the COS.
Williamson et al. Trials 2012, 13:132 Page 5 of 8
http://www.trialsjournal.com/content/13/1/132example, the developers of measurement instruments in
the area of interest may have overtly or covertly manipu-
lated the process of consensus development.
Registration with COMET
One of the aims of the COMET Initiative is to provide
a means of identifying existing, ongoing and planned
COS studies. COS developers should be encouraged toregister their project with COMET. The following in-
formation about the scope and methods used will be
recorded in the database for existing and ongoing
work:
1. Clinical areas for which the outcome domains or
outcomes are being considered, identifying both
primary disease and types of intervention.
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including the information participants will receive
beforehand to inform their answers, and the methods
to be used to reduce any list of possible outcomes.
3. People and organizations involved in identifying and
selecting the outcome domains or outcomes,
recording how the relative contributions will be used
to define the COS.
4. The geographical setting(s) of the study.
Details of any associated publications, including the
final report describing whether consensus has been
reached, and the outcome domains and outcomes that
were included in the COS, will be recorded in the data-
base. Currently, the database includes studies ranging
from the development of a specific COS using formal
consensus methods, to a systematic review of outcomes
measured in clinical trials in a particular area that may
inform future COS development. Articles are classified
according to the methods used therein.
Discussion
Various methods have been used to develop a COS and it
is uncertain which are most suitable, accurate and effi-
cient. There is limited empirical evidence regarding
whether different methods lead to similar or different con-
clusions. One example where consensus work has been
undertaken in two different ways is in pediatric asthma.
The American Thoracic Society/European Respiratory So-
ciety employed an expert panel approach [28], whereas
other researchers combined results from a Delphi survey
with clinicians and interviews with parents and children.
The results were overlapping but not identical [10].
A systematic review of all COS development projects
is ongoing, extending a previous review of pediatric
studies [16]. This involves a survey of and interviews
with COS developers in order to understand their choice
of approach, to describe their experience of COS devel-
opment and implementation, and to identify priority
areas for methodological research. It is evident that the
reporting of COS development studies requires improve-
ment [29], and as the number of COS studies increases
it is important to identify a minimum amount of infor-
mation to be included in future publications. It is to be
expected that the proposed checklist (Table 1) will de-
velop over time, in a similar way to the CONSORT
statement [30], based on accumulating evidence. A qual-
ity assessment tool will also be developed, using
accepted methods [31].
The methods for COS development need to be suffi-
ciently rigorous so as to avoid those situations in which
a COS is recommended but subsequently found to be
deficient in some way because of the methods used to
develop it. Establishing a COS using rigorous methodswill also help in setting the threshold for changing it,
which arguably should be high, as it is in OMERACT
[13]. For example, the original OMERACT core set in
rheumatoid arthritis was established without direct pa-
tient input; but focus groups were held at OMERACT 6
(in 2002), the first OMERACT meeting that patients
were invited to attend. Supported by a previous email
survey, fatigue and sleep were identified as missing from
the OMERACT core set, which only included pain, func-
tion, joint counts, global assessments and a blood test.
The experience of fatigue has been reported by a large
proportion of people with rheumatoid arthritis, and it is
often the most important problem for individual
patients. A systematic analysis of these patient focus
group discussions revealed three overarching themes: fa-
tigue is overwhelming and different from normal tired-
ness; it permeates every sphere of life; and self-
management is variable, but professional support is rare.
Over the next two years a systematic search for articles
measuring fatigue discovered twenty-three scales, six of
which had sufficient evidence of validity to pass most of
the OMERACT filter for truth, discrimination and feasi-
bility [13]. Further work to demonstrate responsiveness
was then undertaken and in 2006 fatigue was endorsed
as an additional core outcome by a vote at the OMER-
ACT 8 meeting [32].
As noted above, another important consideration is
the question of who should be developing and reviewing
COS (for example, professional organizations or groups
of trialists in particular therapeutic areas). The collation
and review of empirical evidence concerning dissemin-
ation methods and strategies to encourage uptake are
other important aspects of the work that need to be con-
sidered early in the process.
Conclusion
The COMET Initiative provides a focus for the contin-
ued development of a framework for outcome measure-
ment, first in relation to domains and outcomes within
domains, subsequently in terms of definitions and meas-
urement instruments, and finally in relation to the tim-
ing of measurement. There is an increasing awareness of
the need for greater attention to be given to the out-
comes measured in clinical trials, in terms of
standardization and reporting. Consideration of the
issues and the checklist described should help with the
development, reporting and implementation of COS.
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